Medicenna Therapeutics Corp.
MDNAF
Medicenna Therapeutics Corp. is a clinical-stage biotechnology company specializing in the development of advanced immunotherapies for cancer and other challenging diseases. Leveraging its proprietary Superkine Platform, Medicenna engineers powerful and highly selective interleukin-based therapeutics known as Superkines. These novel proteins are designed to precisely modulate and amplify the immune response, targeting key cellular pathways to enhance anti-tumor immunity or address autoimmune conditions. The company’s pipeline includes Superkines such as MDNA11, an engineered IL-2 variant optimized for cancer immunotherapy, and MDNA55, an IL-4 empowered cytotoxin developed for recurrent glioblastoma, a form of brain cancer. Additional candidates address various solid tumors and autoimmune diseases, utilizing mechanisms that either stimulate immune cell activity or inhibit disease-promoting cytokine signaling. Medicenna’s innovative technologies are geared toward tackling diseases with significant unmet need, emphasizing scientific rigor and patient-centered outcomes. The company maintains a focused mission to transform the therapeutic landscape through next-generation immunotherapies, underpinned by a commitment to advancing cytokine biology and translational medicine.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$0.00
Net Income (TTM)
-C$19M
▼ -55.9% YoY
Op. Margin
–
ROIC
-162.00%
▼ -30.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$19M
▼ -8.5% YoY
Op. Cash Flow (TTM)
-C$19M
▼ -66.5% YoY
Net Debt
-C$6M
Net Cash Position
Cash & Equiv.
C$6M
Continue Research
Peers
Biotechnology · Pick stocks to compare with MDNAF
Medicenna Therapeutics (MDNAF) in three numbers
- Quality score
- 20/100
- Best check: share count change, -7.9%. Weakest: return on capital, -162.0%.
- Quality
Questions about Medicenna Therapeutics
Is Medicenna Therapeutics a high-quality business?
Medicenna Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at -7.9%, and its weakest is return on capital at -162.0%. The Quality tab shows every check against its target.
Does Medicenna Therapeutics (MDNAF) pay a dividend?
No. Medicenna Therapeutics (MDNAF) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MDNAF
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.